Dr. Dima Dandachi, M.D
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 34
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MO license 2018016511 -
Student in an Organized Health Care Education/Training Program
IL license 036138486
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Missouri Health Care Columbia, MO
Medical groups
- The Curators of the University of Missouri (1,131 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 34
- Services billed
- 84
- Patients’ average age
- 60
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 60 | 47 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Shingrix (varicella-zoster ge/as01b/pf) Other prescribers in Columbia, MO | 40 |
| Abrysvo (rsv vacc, pref a and pref b/pf) Other prescribers in Columbia, MO | 37 |
| Boostrix Tdap (diphth,pertuss(acell),tet vac) Other prescribers in Columbia, MO | 28 |
| Biktarvy (bictegrav/emtricit/tenofov ala) | 15 |
| Dovato (dolutegravir sodium/lamivudine) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 109 payments worth $92,742 in total to this clinician.
| Gilead Sciences, Inc. | $48,346 |
|---|---|
| Viiv Healthcare Company | $44,395 |
| Compensation for services other than consulting (speaking, faculty) | $68,360 |
|---|---|
| Travel and Lodging | $12,955 |
| Consulting Fee | $8,355 |
| Food and Beverage | $3,072 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Viiv Healthcare Company Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $7,150 |
| Viiv Healthcare Company Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $7,150 |
| Gilead Sciences, Inc. Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4027423;GTF;11356658 | $6,750 |
| Gilead Sciences, Inc. Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4176334;AHM;11356658 | $5,020 |
| Gilead Sciences, Inc. Dec 16, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4269560;AHM;11356658 | $5,020 |
| Viiv Healthcare Company Sep 10, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $3,900 |
| Gilead Sciences, Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4113469;AHM;11356658 | $3,840 |
| Gilead Sciences, Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4259721;AHM;11356658 | $3,840 |
| Gilead Sciences, Inc. Feb 10, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4113475;AHM;11356658 | $2,950 |
| Gilead Sciences, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4264060;AHM;11356658 | $2,950 |
All 60 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Dec 19, 2025 | Travel and Lodging travel to Los Angeles, CA · in-kind Company’s description;4269114;AHM;11356658 | $202 |
| Gilead Sciences, Inc. Dec 19, 2025 | Travel and Lodging travel to Los Angeles, CA · in-kind Company’s description;4268733;AHM;11356658 | $60.00 |
| Gilead Sciences, Inc. Dec 16, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4269560;AHM;11356658 | $5,020 |
| Gilead Sciences, Inc. Dec 2, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4261854;AHM;11356658 | $2,065 |
| Gilead Sciences, Inc. Dec 2, 2025 | Travel and Lodging travel to Los Angeles, CA · in-kind Company’s description;4327826;AHM;11356658 | $1,261 |
| Viiv Healthcare Company Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $7,150 |
| Viiv Healthcare Company Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $1,300 |
| Gilead Sciences, Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4286402;GTF;11356658 | $590 |
| Gilead Sciences, Inc. Nov 20, 2025 | Travel and Lodging travel to Los Angeles, CA · in-kind Company’s description;4269430;AHM;11356658 | $472 |
| Viiv Healthcare Company Nov 13, 2025 | Travel and Lodging CABENUVA · HIV · travel to Columbia, MO | $311 |
| Gilead Sciences, Inc. Nov 10, 2025 | Travel and Lodging travel to Los Angeles, CA · in-kind Company’s description;4269441;AHM;11356658 | $1,350 |
| Gilead Sciences, Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4285780;GTF;11356658 | $590 |
| Gilead Sciences, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4264060;AHM;11356658 | $2,950 |
| Viiv Healthcare Company Oct 7, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $238 |
| Gilead Sciences, Inc. Sep 30, 2025 | Travel and Lodging Biktarvy · HIV · travel to Kansas City, MO · in-kind Company’s description;4259717;AHM;11356658 | $185 |
| Gilead Sciences, Inc. Sep 30, 2025 | Travel and Lodging Biktarvy · HIV · travel to Kansas City, MO · in-kind Company’s description;4259547;AHM;11356658 | $20.00 |
| Viiv Healthcare Company Sep 29, 2025 | Travel and Lodging CABENUVA · HIV · travel to Wichita, KS | $188 |
| Viiv Healthcare Company Sep 18, 2025 | Consulting Fee | $2,275 |
| Gilead Sciences, Inc. Sep 11, 2025 | Travel and Lodging Biktarvy · HIV · travel to Omaha, NE · in-kind Company’s description;4176712;AHM;11356658 | $438 |
| Gilead Sciences, Inc. Sep 11, 2025 | Travel and Lodging Biktarvy · HIV · travel to Omaha, NE · in-kind Company’s description;4176022;AHM;11356658 | $38.50 |
| Viiv Healthcare Company Sep 10, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $3,900 |
| Gilead Sciences, Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4259721;AHM;11356658 | $3,840 |
| Gilead Sciences, Inc. Sep 4, 2025 | Travel and Lodging Biktarvy · HIV · travel to Kansas City, MO · in-kind Company’s description;4259897;AHM;11356658 | $188 |
| Viiv Healthcare Company Aug 21, 2025 | Travel and Lodging CABENUVA · HIV · travel to Wichita, KS · in-kind | $1,328 |
| Viiv Healthcare Company Aug 21, 2025 | Travel and Lodging CABENUVA · HIV · travel to Wichita, KS · in-kind | $127 |
| Viiv Healthcare Company Aug 14, 2025 | Travel and Lodging travel to Washington, DC · in-kind | $242 |
| Gilead Sciences, Inc. Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4176334;AHM;11356658 | $5,020 |
| Viiv Healthcare Company Aug 12, 2025 | Consulting Fee | $2,600 |
| Gilead Sciences, Inc. Aug 11, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4257566;AHM;11356658 | $2,065 |
| Gilead Sciences, Inc. Aug 7, 2025 | Travel and Lodging Biktarvy · HIV · travel to Omaha, NE · in-kind Company’s description;4177105;AHM;11356658 | $370 |
| Viiv Healthcare Company Jul 23, 2025 | Travel and Lodging CABENUVA · HIV · travel to Springfield, IL | $302 |
| Viiv Healthcare Company Jul 23, 2025 | Travel and Lodging CABENUVA · HIV · travel to Kansas City, MO | $199 |
| Viiv Healthcare Company Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company Jul 14, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company Jul 14, 2025 | Travel and Lodging CABENUVA · HIV · travel to Saint Louis, MO | $188 |
| Gilead Sciences, Inc. Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4128237;AHM;11356658 | $1,480 |
| Viiv Healthcare Company Jun 25, 2025 | Travel and Lodging CABENUVA · HIV · travel to Kansas City, MO · in-kind | $242 |
| Viiv Healthcare Company Jun 23, 2025 | Travel and Lodging CABENUVA · HIV · travel to Springfield, IL · in-kind | $412 |
| Viiv Healthcare Company Jun 18, 2025 | Travel and Lodging travel to Washington, DC · in-kind | $337 |
| Viiv Healthcare Company Jun 18, 2025 | Travel and Lodging travel to Washington, DC · in-kind | $42.18 |
| Viiv Healthcare Company Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $1,300 |
| Viiv Healthcare Company Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $7,150 |
| Viiv Healthcare Company Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) CABENUVA · HIV | $2,600 |
| Viiv Healthcare Company May 20, 2025 | Travel and Lodging CABENUVA · HIV · travel to Columbia, MO | $303 |
| Viiv Healthcare Company May 20, 2025 | Travel and Lodging CABENUVA · HIV · travel to Columbia, MO | $8.00 |
| Gilead Sciences, Inc. May 14, 2025 | Travel and Lodging Biktarvy · HIV · travel to Dallas, TX Company’s description;4027766;GTF;11356658 | $33.60 |
| Gilead Sciences, Inc. Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4027423;GTF;11356658 | $6,750 |
| Gilead Sciences, Inc. Apr 16, 2025 | Travel and Lodging Biktarvy · HIV · travel to Kansas City, MO · in-kind Company’s description;4098491;AHM;11356658 | $186 |
| Gilead Sciences, Inc. Apr 4, 2025 | Travel and Lodging Biktarvy · HIV · travel to Dallas, TX · in-kind Company’s description;4027523;GTF;11356658 | $330 |
| Gilead Sciences, Inc. Apr 4, 2025 | Travel and Lodging Biktarvy · HIV · travel to Dallas, TX · in-kind Company’s description;4027384;GTF;11356658 | $101 |
| Gilead Sciences, Inc. Apr 3, 2025 | Travel and Lodging Biktarvy · HIV · travel to Dallas, TX · in-kind Company’s description;4027524;GTF;11356658 | $933 |
| Gilead Sciences, Inc. Apr 3, 2025 | Travel and Lodging Biktarvy · HIV · travel to Dallas, TX · in-kind Company’s description;4027484;GTF;11356658 | $296 |
| Gilead Sciences, Inc. Mar 31, 2025 | Consulting FeeCompany’s description;4146878;VEM US;11356658 | $1,740 |
| Gilead Sciences, Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4113469;AHM;11356658 | $3,840 |
| Gilead Sciences, Inc. Mar 6, 2025 | Consulting FeeCompany’s description;4146842;VEM US;11356658 | $1,740 |
| Viiv Healthcare Company Feb 28, 2025 | Travel and Lodging travel to Hollywood, FL · in-kind | $945 |
| Gilead Sciences, Inc. Feb 10, 2025 | Compensation for services other than consulting (speaking, faculty) Biktarvy · HIV Company’s description;4113475;AHM;11356658 | $2,950 |
| Viiv Healthcare Company Jan 22, 2025 | Travel and Lodging travel to Hollywood, FL · in-kind | $1,037 |
| Viiv Healthcare Company Jan 22, 2025 | Travel and Lodging travel to Hollywood, FL · in-kind | $41.79 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $498,569 in research payments for these studies, mostly to the institutions running them.
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Mannkind Corporation · Terminated · NCT06418711 - ACCELERATE a Multisite Prospective Hybrid (Effectiveness-implementation) Type 2 Design, Single-arm, Mixed-methods Study of a Simplified Accelerated ART Initiation Protocol for People With HIV Who Are Out of Care.
Gilead Sciences, Inc. - A phase 2B multicenter, randomized, open-label study comparing the eff
Viiv Healthcare Company - Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre,…
Dompe Farmaceutici S.p.a. - Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with Acute Respiratory …
Dompe Farmaceutici S.p.a. - A phase 4, randomized, open-label, two-arm study evaluating implementa
Viiv Healthcare Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.